Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $40.67

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have received a consensus rating of “Hold” from the eleven analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $41.4444.

A number of analysts have recently weighed in on the stock. The Goldman Sachs Group upped their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday. Leerink Partners lifted their price objective on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, December 26th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Friday, March 27th. Citigroup upped their target price on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 22nd.

Agios Pharmaceuticals Stock Up 3.0%

AGIO opened at $35.20 on Tuesday. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -4.95 and a beta of 0.79. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The company has a 50-day simple moving average of $28.75 and a 200 day simple moving average of $32.21.

Insiders Place Their Bets

In related news, insider Tsveta Milanova sold 2,872 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $27.02, for a total transaction of $77,601.44. Following the completion of the sale, the insider directly owned 34,793 shares in the company, valued at $940,106.86. This represents a 7.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Krishnan Viswanadhan sold 2,959 shares of the firm’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $27.80, for a total value of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares in the company, valued at $142,919.80. This trade represents a 36.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 4.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. bought a new stake in shares of Agios Pharmaceuticals during the 4th quarter valued at approximately $25,000. First Horizon Corp bought a new position in Agios Pharmaceuticals in the 3rd quarter valued at approximately $45,000. Assetmark Inc. boosted its position in Agios Pharmaceuticals by 37.9% in the fourth quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 362 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals in the first quarter valued at approximately $40,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $49,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.